Print Icon
 
   
   

February 2022

Clinical Update: 

NCCN Updates Guidelines 

for Treatment of Prostate Cancer

The National Comprehensive Cancer Network (NCCN) Guidelines for Prostate Cancer focus on the screening, diagnosis, staging, treatment, and management considering individual risk assessment.


These updated guidelines include criteria for further genetic risk evaluation using a hereditary cancer panel for hereditary cancer syndromes:


  • Close family history of known pathogenic variations or cancer,
  • Metastatic, regional, very-high risk localized, high-risk localized prostate cancer, OR
  • Tumors with certain histological characteristics.


Germline testing should be considered in appropriate individuals where it will likely impact the treatment, clinical trial options and risk management. The recommended panels should contain BRCA1, BRCA2, ATM, PALB2, CHEK2, MLH1, MSH2, MSH6, and PMS2.


Genetics Institute of America’s GIAnomics™ Hereditary Cancer Panel includes all the recommended predisposition genes for RCC. GIA is committed to exceeding the standards put forth by prestigious organizations, like NCCN, and ensuring that the panels we offer support your medical needs and your patient’s health and safety.

   
   

Enroll your Practice in GH-101!


Genetics Institute of America is actively recruiting practices to join our study, GH-101! The objective of this study is to take an integrative approach to the fields of pharmacogenomics, cancer genomics, mRNA microarrays and nutrigenomics by identifying DNA and RNA variants in persons with chronic disease. We are looking for Physicians and Physician Groups that currently treat patients with a chronic disease including: cancer, cardiac conditions, diabetes, kidney disease, PTSD. Getting your practice involved is easy and not only gets patients the individualized health information they need but allows your practice to be on the cutting edge of genetic research. Click "Enroll Now" for more information about this study and enrolling your practice.


   

Have you Seen This?: 


High Prevalence of Germline Variations in Renal Cell Carcinoma Patients

   

Using genomic biomarker tests has become a cornerstone in personalized cancer treatment and has increased overall survival.

It's All in the Genes:


Prevalence of Pathogenic Variants in Pancreatic Cancer Patients

   

Pancreatic cancer (PC) has one of the worst overall survival rates compared to other cancer types.1 With approximately 58,000 new cases diagnosed in the United States in 2020, the 5-year survival rate is lower than 10%.

Changing Corporate Culture:


Love for Orphans Across the World

Genetics Institute of America believes that it is our responsibility to care for the community we are a part of, and that corporate culture can do more to play a greater role in community solutions.


   
   
   

Thank you for the trust and confidence you have placed in our team here at the Genetics Institute of America. This monthly newsletter is our primary method of communicating to you important information about our testing and assays, general information about the Genetics Institute, as well as information impacting patient care and safety. If you would like to have another person in your practice receive these updates, please forward this to them so that they can subscribe.


   

Ana Perez-Miranda, PhD, MDxT (AAB), MB (ASCP)

Laboratory Manager and Molecular Diagnostics Supervisor

Genetics Institute of America

   

GIA Lab News is an educational service of Genetics Institute of America.


Genetics Institute of America is a national laboratory dedicated to heightening the awareness of early intervention and genetic screening to promote the longevity and quality of life outcomes. Our determination and research allow us to provide next generation DNA sequencing to deliver customized testing for identified genetic related cancers and other diseases.

Follow Us On

4733 W. Atlantic Ave, Suite C16

Delray Beach, FL 33445

Phone: (833) 4GENLAB or (833) 443-6522

HIPAA Fax: (561) 354-5369


You are receiving this email because you opted into receiving communications from Genetics Institute of America online or verbally on the phone, and/or maintain a professional relationship with our laboratory. From time to time, we’ll send newsletters, blog articles, and other educational clinical updates to our subscribers. We hope you find them useful. If not, you can unsubscribe from our list here.


Who do you know that needs to know? Forward this email

Did someone forward this to you? Subscribe

Want to change how you receive these emails?

You can Unsubscribe or Update your preferences.


© 2022 Genetics Institute of America. All Rights Reserved.